Sexual wellness
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients
Feifel D, Macdonald K, Nguyen A, et al. · Biol Psychiatry · 2010
PMID: 20970778 · DOI: 10.1016/j.biopsych.2010.09.017
Summary
Randomized double-blind placebo-controlled crossover study of intranasal oxytocin adjunctive to antipsychotics in schizophrenia. Endpoints: PANSS total, social-cognition measures across the dosing period.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
More Sexual wellness citations
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsObstet Gynecol · 2019
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderObstet Gynecol · 2019
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunctionInt J Impot Res · 2004